SCSE-OAC: Self-care and Self-efficacy Scale in Oral Anticoagulation Therapy

IRCCS Policlinico S. Donato (Other)
Overall Status
Not yet recruiting ID

Study Details

Study Description

Brief Summary

This study aims to develop and validate an index measurement tool to assess the patient's self-care self-efficacy in managing oral anticoagulation therapy (OAC). The index measure (i.e., SCSE-OAC) will be tested for its cross-cultural validity and reliability for the English and Italian-speaking population. For these reasons, a multi-phase and mixed-method observational and cross-sectional study design will be conducted.

Condition or Disease Intervention/Treatment Phase
  • Other: Self-assess and reporting self-care self-efficacy levels

Detailed Description

Oral anticoagulation therapy (OAC) is the most suitable treatment worldwide for the primary and secondary prevention of thromboembolism and stroke in patients with non-valvular atrial fibrillation (NVAF). However, the strategies to provide an optimal quality of anticoagulation control are still an open challenge for healthcare professionals. In this regard, understanding the health determinants underline the patient's adherence is fundamental in the research field to develop personalized patient-centered education interventions in clinical practice and consequently avoid low treatment adherence. Among these health determinants (e.g., patients' knowledge, health literacy, beliefs, etc), the patients' self-efficacy is underreported because a specific tool is not yet available to measure patients' self-efficacy regarding the health behaviors challenges in OAC self-care management.

The primary aim of this study is to develop the patients' self-care self-efficacy index in oral anticoagulation therapy management (SCSE-OAC) in adults with non-valvular atrial fibrillation and provide cross-cultural validity and reliability of the developed index measure.

More specifically, to assess the internal validity of the SCSE-OAC, content and construct validity proprieties will be tested for each translated version of the SECSE-OAC, as well as its reliability and invariance characteristics.

Study Design

Study Type:
Anticipated Enrollment :
312 participants
Observational Model:
Time Perspective:
Official Title:
Patients' Self-care and Self-efficacy Scale in Oral Anticoagulation Therapy (SCSE-OAC): A Bilingual/Multi-national Mixed-method Validation Study
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Non-valvular atrial fibrillation (NVAF) patients treated with oral anticoagulants

Adult outpatients (≥ 18 years) with NVAF and treated with OAC for at least three months.

Other: Self-assess and reporting self-care self-efficacy levels
Patients will have to self-report the self-care self-efficacy levels they experienced in managing the OAC therapy.

Outcome Measures

Primary Outcome Measures

  1. SCSE-OAC index [data collection will perform at the first 1 day patient visit]

    The SCSE-OAC measurement index will provide evidence about the level patients perceive in their skills in facing daily challenges in managing their oral anticoagulation therapy. Furthermore, evidence of the validity and reliability of the SCSE-OAC tool will be provided for each native-speaking country involved in the study.

Eligibility Criteria


Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • Age ≥ 18 years

  • Diagnosis of non-valvular atrial fibrillation

  • Outpatients

  • Treating with any OAC for at least three months before enrollment

  • Patients willing to participate in the study and provide informed consent

Exclusion Criteria:
  • Patients treated with OAC for a brief period (i.e., less than three months)

  • Patients with serious comorbidity (i.e, Charlson Comorbidity Index, ICC > 4)

  • Patients who have suspended OAC for surgery in the last three months

  • Cognitive impairment (assessed using six-item screener, SIS < 4)

Contacts and Locations


No locations specified.

Sponsors and Collaborators

  • IRCCS Policlinico S. Donato


None specified.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Arianna Magon, Principal Investigator, IRCCS Policlinico S. Donato Identifier:
Other Study ID Numbers:
  • 164/INT/2022
First Posted:
Apr 20, 2023
Last Update Posted:
Apr 20, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:

Study Results

No Results Posted as of Apr 20, 2023